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Sir,
We read with great interest the letter by Coon et al. [1],
recently published in this journal and we would like to
focus our attention on the following concerns regarding
this report:
1. Burning mouth syndrome is a chronic, idiopathic oral
mucosal pain/discomfort, in which no clinical lesions
or systemic diseases or other causes, especially drugs
are identified [2, 3]. Some authors have used the term
‘‘secondary BMS’’ to indicate a form of oral complaint
caused by local/systemic pathological conditions
(including drugs), but even this term seems to be
inappropriate, as the term ‘‘BMS’’ automatically
excludes any known cause of any type of oropharyn-
geal complaint. Clinically, it is absolutely mandatory
to differentiate between any oral burning, which can
have many different causes (including drugs) and
BMS, which describes a separate idiopathic clinico-
pathological entity. Therefore, if this patient’s oral
burning had been caused by carbidopa/levodopa, it
would have been more appropriate to make a diagnosis
of ‘‘carbidopa/levodopa-induced oral burning’’ and not
‘‘BMS or secondary BMS’’.
2. If authors have suspected an adverse reaction to a
specific drug, a reader might wonder why no one of the
adverse drug reaction (ADR) algorithms [4, 5] has
been used and no specific guideline [6] has been
followed to conclusively prove a causative-relation-
ship between oral burning sensation and carbidopa/
levodopa.
3. In addition, one of these ADR algorithms would have
helped clinicians in better differentiating between an
oral burning induced by carbidopa/levodopa and an
oral burning simply as a manifestation of Parkinson’s
disease (PD). Indeed, considering the high association
between PD and oral burning [7], PD might have
caused this oral discomfort on its own.
4. Last, but not less important, it is necessary to distinguish
an oral burning sensation as a clinical manifestation of
an anxiety/depression trait or PD, considering either the
association between PD and depressive symptoms
(45 %) [8] and anxiety (50 %) [9] or between anxiety,
depression and idiopathic BMS [10].
Rebus sic stantibus, it seems hard to establish where
does this oral burning really come from (carbidopa/levo-
dopa, PD, anxiety/depression, or a combination of these
variables?) This case highlights, for all health care pro-
fessionals, the need of a more rigorous diagnostic protocol
before drawing any conclusion on a possible etiology of
any oropharyngeal complaint.
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